All Posts
Long-term follow-up of a RCT | Endoscopic versus surgical step-up approach for infected necrotizing pancreatitis.
14 Sep, 2022 | 13:13h | UTC
Commentary on Twitter
Long term follow-up #TENSION trial 🇳🇱, today @AGA_Gastro: Endoscopic step-up approach not superior to surgical step-up approach in pts with infected necrotizing #pancreatitis. With endoscopy: ⬇️ pancreaticocutaneous fistulas and ⬇️ re-interventions. https://t.co/WKP7Pwb3vG pic.twitter.com/CGgd3jiTxm
— Marc Besselink (@MarcBesselink) May 18, 2022
Under a Creative Commons Attribution (CC BY 4.0) License
M-A of randomized trials | In patients hospitalized with community-acquired pneumonia, corticosteroids reduce the need for mechanical ventilation without significant effects on mortality, treatment failure, or adverse events.
14 Sep, 2022 | 13:16h | UTCEffect of corticosteroids on mortality and clinical cure in community-acquired pneumonia: A systematic review, meta-analysis, and meta-regression of randomized control trials – CHEST Journal (link to abstract – $ for full-text)
Perspective | Redefining critical illness.
14 Sep, 2022 | 13:13h | UTCRedefining critical illness – Nature Medicine
Review | Multisystem inflammatory syndrome in children (MIS-C) and neonates (MIS-N) associated with COVID-19: optimizing definition and management.
14 Sep, 2022 | 13:15h | UTC
Commentary on Twitter
Proposed classification of Multisystem inflammatory syndrome in #neonates (MIS-N)
Clinical features
Treatment and immunological mechanisms#MISC #covid19 #PIMSTS #PedsICU#NeoEBM @DrSBagci #NeoTwitter #Neonatology @DrKenRemy1 @ChrisCarrollMD @lizWWyld https://t.co/tDuM51GMr4 pic.twitter.com/PNobOOzevX— Yonca Bulut M.D. (@yoncabulutmd) September 6, 2022
Under a http://creativecommons.org/licenses/by/4.0/ License
Systematic Review | Interventions for improving mobility after hip fracture surgery in adults.
14 Sep, 2022 | 13:11h | UTCInterventions for improving mobility after hip fracture surgery in adults – Cochrane Library
Commentary from the author on Twitter
Pleased to have our Cochrane review on mobility training after hip fracture out today. Key message “extra exercises targeting balance, walking and functional tasks appear effective in improving mobility in hospital and after discharge.” @msk_health https://t.co/vLbGWKZWgp
— Prof Cathie Sherrington (@CathieSherr) September 7, 2022
Systematic Review | Maternal postures for fetal malposition in labor for improving the health of mothers and their infants.
14 Sep, 2022 | 13:12h | UTCSummary: Mothers’ positions in labour when baby is lying ‘back-to-back’ – Cochrane Library
M-A | Antibiotic use in ambulatory care for acutely ill children in high-income countries.
14 Sep, 2022 | 13:10h | UTC
M-A of randomized trials | Digital health interventions for musculoskeletal pain conditions.
14 Sep, 2022 | 13:08h | UTC
Retrospective Cohort Study | Natural history of MYH7-related dilated cardiomyopathy.
14 Sep, 2022 | 13:06h | UTC
M-A of randomized trials | Effectiveness of work-related interventions for return to work in people on sick leave.
14 Sep, 2022 | 13:08h | UTC
Review | Nutritional support for pediatric severe traumatic brain injury.
14 Sep, 2022 | 13:04h | UTCNutritional Support for Pediatric Severe Traumatic Brain Injury – Frontiers in Pediatrics
Cohort Study | Incidence of antipsychotic use among community dwellers with and without Parkinson’s disease.
14 Sep, 2022 | 13:07h | UTCCommentaries:
Elevated Incidence of Antipsychotic Use Found Prior to Parkinson Disease Diagnosis – AJMC
Antipsychotics Use Climbs in Years Before Parkinson’s Diagnosis: Study – Parkinson’s News Today
Expert Opinion | Clinical management of pregnancy in women with polycystic ovary syndrome.
14 Sep, 2022 | 13:02h | UTC
M-A | The effectiveness of self-care interventions in chronic illness.
14 Sep, 2022 | 13:03h | UTC
Phase 2 RCT | Sequencing of Ipilimumab plus Nivolumab and Encorafenib plus Binimetinib for untreated BRAF-mutated metastatic melanoma.
14 Sep, 2022 | 13:01h | UTCSequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Data from the phase II SECOMBIT trial of treatment sequencing for BRAF-mutant metastatic melanoma suggests that nivo+ipi followed by encorafenib + binimetinib results in better OS than the reverse sequence, although with a greater risk of grade 3-4 AEs: https://t.co/9jC2oMI4Az
— NatureRevClinOncol (@NatRevClinOncol) September 7, 2022
RCT | Efficacy and safety of carboplatin with nab-paclitaxel vs. docetaxel in older patients with squamous non-small-cell lung cancer.
14 Sep, 2022 | 13:00h | UTC
Commentary on Twitter
New research: in a ph3 RCT pts aged 70 yrs and older with squamous non-small-cell #lungcancer, overall survival was significantly longer with #carboplatin & nab-paclitaxel vs #docetaxel
👉https://t.co/qOuaVpO61f pic.twitter.com/TSnMguOkoR— The Lancet Healthy Longevity (@LancetLongevity) December 9, 2021
Cohort Study | Aerosol precautions and airway complications.
14 Sep, 2022 | 12:57h | UTC
Commentary on Twitter
🔐FFP2/3 mask use by anaesthetists was associated with increased patient airway complications👇@t_Potter_1 @john_n_cronin @justin_kua @EvieNurmi @dannyjnwong @dr_imranahmad @doctimcook @elboghdadly @PeriopResearch @STAResearch @SQuAResNet @NWRAG
🔗https://t.co/NnJZqGzU4R pic.twitter.com/PhSsU0KcGC
— 𝘈𝘯𝘢𝘦𝘴𝘵𝘩𝘦𝘴𝘪𝘢 (@Anaes_Journal) September 8, 2022
RCT | Dexamethasone is not effective for the treatment of dyspnea in patients with cancer and increases the risk of adverse events.
13 Sep, 2022 | 13:22h | UTCEffect of dexamethasone on dyspnoea in patients with cancer (ABCD): a parallel-group, double-blind, randomised, controlled trial – The Lancet Oncology (free for a limited period)
Commentary on Twitter
Our phase III randomized study, published in Lancet Oncology today, showed high-dose steroid didn’t improve SOB and should not be used routinely in pts with lung ca for SOB palliation. My personal link in Lancet Oncology article ⁰https://t.co/Mj0AAzMujB pic.twitter.com/FMG7csHZsn
— Joe Y Chang (@JoeChangMD) September 7, 2022
Cluster RCT | Tighter vs. less tight glycemic targets for women with gestational diabetes mellitus for reducing maternal and perinatal morbidity.
13 Sep, 2022 | 13:21h | UTC
Dementia: evidence, experience and resources.
13 Sep, 2022 | 13:20h | UTCDementia: evidence, experience and resources – Evidently Cochrane
RCT | A double-dose influenza vaccination during hospitalization for acute coronary syndrome did not improve outcomes compared to standard-dose outpatient vaccination.
13 Sep, 2022 | 13:19h | UTC
Commentary on Twitter
In the VIP-ACS trial, among patients hospitalised with an ACS, double dose influenza vaccination before discharge does not reduce cardiovascular and pulmonary outcomes compared with standard dose vaccination 👉https://t.co/L9e7MXWfWV#EHJ #ESCCongress @ehj_ed @rladeiraslopes pic.twitter.com/95o50krrwm
— European Society of Cardiology Journals (@ESC_Journals) August 31, 2022
Review / Perspective | Which patients with aortic stenosis should be referred to surgery rather than transcatheter aortic valve implantation?
13 Sep, 2022 | 13:18h | UTC
Commentary on Twitter
https://twitter.com/ESC_Journals/status/1526080012729864198
M-A | Blood type linked to the risk of stroke before age 60.
13 Sep, 2022 | 13:17h | UTCContribution of Common Genetic Variants to Risk of Early Onset Ischemic Stroke – Neurology (link to abstract – $ for full-text)
News Releases:
Is your blood type linked to your risk of stroke before age 60? – American Academy of Neurology
Blood Type Linked To Stroke Risk Before 60 – University of Maryland
Radiological assessment of dementia | Consensus for a practical and clinically oriented guide to image acquisition, evaluation, and reporting.
13 Sep, 2022 | 13:13h | UTC
RCT | Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19.
13 Sep, 2022 | 13:16h | UTC
Commentaries on Twitter
Interesting results in the #PANAMO trial of vilobelimab, an anti-C5a antibody, in critically ill ICU patients w/ COVID19.
People on MV (n=386) randomized to vilobelimab vs placebo. Mortality was (maybe) reduced in a subgroup w/ more severe illness…🤔https://t.co/bO5XiRptag
1/ pic.twitter.com/EUNda67T9j— Nick Mark MD (@nickmmark) September 11, 2022
NEW Research—In addition to SOC, vilobelimab improves survival of invasive mechanically ventilated patients w/ #COVID19 and leads to a significant decrease in mortality
Read the PANAMO study from Prof Alexander Vlaar & colleagues here https://t.co/k5UuqQtqyE pic.twitter.com/Xmrb76ZpzW
— The Lancet Respiratory Medicine (@LancetRespirMed) September 8, 2022